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Phenotypic characteristics of early Wolfram
syndrome
Bess A Marshall1,15*, M Alan Permutt2ˆ, Alexander R Paciorkowski3,4,5, James Hoekel1,6,14, Roanne Karzon7,8,14,
Jon Wasson2, Amy Viehover1,9, Neil H White1,2,14, Joshua S Shimony10, Linda Manwaring1, Paul Austin11,12,
Timothy E Hullar7, Tamara Hershey9,10,13 and the Washington University Wolfram Study Group

Abstract
Background: Wolfram Syndrome (WFS:OMIM 222300) is an autosomal recessive, progressive, neurologic and
endocrinologic degenerative disorder caused by mutations in the WFS1 gene, encoding the endoplasmic reticulum
(ER) protein wolframin, thought to be involved in the regulation of ER stress. This paper reports a cross section of
data from the Washington University WFS Research Clinic, a longitudinal study to collect detailed phenotypic data
on a group of young subjects in preparation for studies of therapeutic interventions.
Methods: Eighteen subjects (ages 5.9–25.8, mean 14.2 years) with genetically confirmed WFS were identified
through the Washington University International Wolfram Registry. Examinations included: general medical,
neurologic, ophthalmologic, audiologic, vestibular, and urologic exams, cognitive testing and neuroimaging.
Results: Seventeen (94%) had diabetes mellitus with the average age of diabetes onset of 6.3 ± 3.5 years. Diabetes
insipidus was diagnosed in 13 (72%) at an average age of 10.6 ± 3.3 years. Seventeen (94%) had optic disc pallor
and defects in color vision, 14 (78%) had hearing loss and 13 (72%) had olfactory defects, eight (44%) had impaired
vibration sensation. Enuresis was reported by four (22%) and nocturia by three (17%). Of the 11 tested for bladder
emptying, five (45%) had elevated post-void residual bladder volume.
Conclusions: WFS causes multiple endocrine and neurologic deficits detectable on exam, even early in the course
of the disease. Defects in olfaction have been underappreciated. The proposed mechanism of these deficits in WFS
is ER stress-induced damage to neuronal and hormone-producing cells. This group of subjects with detailed clinical
phenotyping provides a pool for testing proposed treatments for ER stress. Longitudinal follow-up is necessary for
establishing the natural history and identifying potential biomarkers of progression.
Keywords: Diabetes mellitus, DIDMOAD, Diabetes insipidus, Hearing loss, Optic atrophy, Color blindness,
Neurodegenerative disorder

Background
Wolfram syndrome (WFS) (OMIM #222300) is a rare
autosomal recessive genetic disease characterized by insulin dependent diabetes mellitus, optic atrophy, blindness,
hearing loss, and other neurological dysfunctions resulting
in death from widespread neurodegeneration in the third
or fourth decade [1]. The causative gene (WFS1) [2],
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which encodes the wolframin protein, has been identified,
and a number of loss-of-function mutations have been described [2,3]. Cell [4] and animal models [5] have led to
the discovery that the wolframin protein resides in the
endoplasmic reticulum (ER) membrane [6], and that
mutant forms predispose insulin-producing pancreatic
β-cells to ER stress-mediated apoptosis [7-9]. Both type
1 and type 2 diabetes have been shown to result from a
variety of genetic risk factors and environmental components. These factors impinge on pancreatic β-cells
resulting in ER stress, oxidative stress, impaired signal
transduction, and mitochondrial dysfunction, all combining to result in β-cell apoptosis and diabetes[10-13].

© 2013 Marshall et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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The complexity of type 1 and type 2 diabetes makes it
difficult to discern the contribution of any one gene or
pathogenic mechanism. In contrast to the multifactorial
etiology of diabetes, subjects with WFS represent an
early-onset form of diabetes and neurodegeneration due
to deficiency of a single protein, making WFS an ideal
model of an ER stress disorder. Currently, no intervention is known to alter the progression or life expectancy
in WFS, but earlier recognition of the syndrome in individuals could improve their quality of life by allowing
earlier intervention for the various debilitating components of WFS.
While there are numerous reports of the features of
WFS from retrospective records [1,3,14-18], there are
no direct, detailed clinical observations of a young cohort studied in one center by the same observers. This
study represents a cross-sectional analysis of a group of
subjects relatively early in the disease with varying duration and manifestations of the syndrome. The ultimate
objective of this study is to observe subjects with WFS
longitudinally beginning early in the disease and to
identify appropriate biomarkers for monitoring disease
progression, thus preparing for future clinical trials.
We report the detailed clinical phenotype of a group of
WFS subjects seen at our annual multidisciplinary
Wolfram Syndrome Research Clinic at Washington
University,

Methods
Subjects

Eighteen participants, 3 of whom were siblings, aged 5 to
25 were recruited through the Washington University
Wolfram Syndrome International Registry website (http://
wolframsyndrome.dom.wustl.edu/medical-research/WolframSyndrome-Home.aspx) to participate in standardized evaluations across domains known to be associated with WFS.
In most cases, subjects initiated joining the registry and
so were self-selected and the investigators further selected those who were young and in the early stages of
the syndrome to take part in the research clinic.
Inclusion criteria for the registry are the diagnosis of
insulin-dependent diabetes mellitus and optic atrophy
by a physician before 18 years of age and/or genetic
confirmation of a WFS1 mutation. Subjects are excluded from the registry if they or a guardian are unable
to speak English or to obtain help with translation and
thus are unable to understand the registry questionnaires. The clinic protocol was approved in advance by
the Washington University Human Research Protection
Office and all subjects provided informed consent if
adults and assent with consent by parents if minor children. Subject’s identification numbers shown in this report are based on their numbers in the registry and are
therefore not necessarily consecutive.
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Methods
Overview

All subjects attended the Washington University WFS
Research Clinic in St. Louis, MO, in August 2010, July
2011, and/or July 2012. This report includes data from
each subject’s initial evaluation. All subjects had a
complete medical and family history and a physical
examination (including a mixed meal challenge test) by
a pediatric endocrinologist (BM or NHW); a neurologic
history and complete neurologic exam by a pediatric
neurologist (AP and AV); visual acuity, refraction, assessment of nystagmus, color vision testing, pupillary
testing and dilated fundus exams by a pediatric optometrist (JH); audiology exams supervised by an audiologist
(RK); complete family history by a genetic counselor
(LM); vestibular examination by an neurotolologist
(TEH); urologic evaluation by a pediatric urologist (PA)
and neuroimaging supervised by a pediatric neuroradiologist (JS), and psychological, and cognitive testing supervised by a neuropsychologist (TH).
Specific tests

Mixed meal challenge tests All subjects but one had
diabetes mellitus and all diabetic subjects were taking insulin either by multiple daily injections (Lantus and a
rapid-acting insulin analog) or by insulin pump. The
night before the oral mixed meal tolerance test, the subjects turned their pump basal rate to 50% of the normal
rate at midnight or took half of their evening dose of
Lantus insulin and fasted from midnight until the test at
8 a.m. The mixed meal consisted of 6 ml/kg (maximum
360 ml) of Boost. Blood for glucose and C-peptide measurement was drawn at time 0 (fasting) and 30 minutes
after the Boost. If a subject’s fasting glucose exceeded
11.1 mmol/l, the test was not performed, but fasting glucose and C-peptide were obtained.

Audiology and vestibular testing Pure tone testing
(250 to 8,000 Hz) was administered via insert earphones
with a Madsen Orbiter 922 audiometer calibrated to
American National Standards Institute [ANSI] S3.6-1996
[19]. WU.WOLF-05 and WU.WOLF-12 were not tested
at the multidisciplinary clinic; audiologic data were
obtained from their local audiologist. To test vestibular
function, harmonic sinusoidal rotations about the earthvertical axis were administered to 8 subjects over the
frequency range of 0.025 to 0.5 Hz at a peak velocity of
60 deg/sec using a clinical rotational chair and video eye
movement-recording device (Micromedical Technologies, Chatham, IL). All subjects were tested only with
low-amplitude rotational stimulation; this is not sensitive
to all vestibular losses.
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Neuroimaging MRI scans were acquired in the Center
for Clinical Imaging Research on a Siemens 3 T Tim
Trio Magnetic Resonance Imaging (MRI) scanner. Blood
glucose was confirmed to be above 4 mmol/l prior to
scanning. T1-weighted (sagittal acquisition, TR = 2,400,
TE = 3.16, TI = 1,000, voxel res = 1 × 1 × 1 mm, frames =
176, Flip = 8, Time = 8:09) and T2 FLAIR images (transverse acquisition, TR = 9,190, TE = 98, TI = 2,500, voxel
res = .86 × .86 × 3 mm, frames = 42, Flip = 150, Time =
3:59) were read by a pediatric neuroradiologist. The
evaluation of the pituitary bright spot was performed
qualitatively by a pediatric neuroradiologist with over
10 years of experience (JSS). The initial interpretation of
the scans was done as they were acquired, however the
final evaluation of the pituitary for all subjects was
performed in one sitting in order to facilitate comparison
across the group.
Cognitive testing Blood glucose was confirmed to be
above 4 mmol/l prior to testing.
The Wechsler Abbreviated Scale of Intelligence (WASI)
[20] Vocabulary and Similarities subtasks were administered to allow us to generate estimated verbal intelligence
quotients (IQ) by comparing to age norms.
University of Pennsylvania smell identification test
(UPSIT) [21] To test olfaction, we administered a
scratch-and-sniff test of common odorants. The UPSIT
has high reliability (test-retest r = 0.94) and established
sensitivity [21]. The UPSIT defines degrees of olfactory
sensitivity based on how many scents the subject identifies correctly. Subjects can be classified as having
normosmia (for age 5–9 = 19 or more correct, for age
10–14 = 32 or more correct, for age 15 and up = 35 or
more correct for female, 34 or more correct for male),
mild microsmia (for age 10–14 = 28–31 correct, for age
15–29 = 31–34 correct for female, 30–33 correct for male),
moderate microsmia (for age 10–14 = 23–27 correct, for
age 15 and up = 26–30 correct for female, 26–29 correct
for male), severe microsmia (for age 10–14 = 19–22
correct, for age 15 and up = 19–25 correct), total anosmia
(6–18 correct), or “probable malingering” (fewer than 6
correct) based on published gender and age-adjusted
norms [22].

Results
Clinical characteristics and mutation analysis

There were 18 subjects with WFS with an average age of
14.2 ± 5.7 years at their first visit to the research clinic.
The ages of the seven male subjects ranged from 7.3 to
22.9 years (average of 13.7 ± 5.4) and the ages of the
eleven female subjects from 5.9 to 25.8 years (average of
14.7 ± 5.8). All subjects had been diagnosed with both
diabetes mellitus (DM) and optic atrophy prior to their
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initial clinic visit except one, who was diagnosed with
WFS due to the presence of insulin requiring diabetes
mellitus and a family history of the condition, and one
who was diagnosed with WFS due to genetic testing
done due to findings of optic atrophy and hearing loss.
Table 1 shows the family and medical history for each
subject.
The average age of onset of DM was 6.3 ± 3.5 years for
the 17 (94%) who had DM. One female, WU.WOLF-19,
had not yet developed DM at age 11.9 years. Of the
remaining ten females, the average age of onset was 6.5 ±
4 years, but without a normal distribution: two were diagnosed in the third year of life, one each in the fourth, fifth,
and sixth, two in the seventh, one in the eighth, then a
skip to the 14th and 15th year of life. Of the male subjects,
the average age of onset of DM was 5.9 ± 2.7, with a similar age distribution to the females except there were no
males who did not have DM by age 10.8 years.
Turning to diabetes insipidus (DI), the average age of
onset for the entire group was 10.6 ± 3.3 years, and 13
subjects (72%) had DI. All of the males had DI with an
average age of onset of 10.5 ± 3.9 years and an age of onset range from 6 to 17 years. Six of the eleven female
(55%) subjects had DI, with an average age of onset of
10.7 ± 2.8 years and a range of 7.5–14.6 years. Those female subjects who did not have DI had an average age
of 13.9 ± 2.7 and a range of 10.8–15.8 years. This suggests that males may have a tendency toward an earlier
onset of DI, though the number of subjects is small.
Optic atrophy was diagnosed in all but one subject
(94%). The average age of diagnosis was 8.7 ± 3.3 years
for all subjects with optic atrophy, 7.5 ± 2.4 (range 5–11)
years for the males, and 9.3 ± 3.7 (range 5–15.3) years
for the females.
Nine subjects (50%) had previously-diagnosed hearing
loss and 5 more (for a total of 78%) were newly diagnosed with hearing loss at the clinic. Six of the seven
male subjects had hearing loss with a mean age of diagnosis of 8.2 ± 2.1 (range 6–11.9) years. The one boy with
no loss still had normal hearing at age 14.3 years. The
mean age of diagnosis of hearing loss in the female subjects was 9.9 years but the group again did not exhibit a
normal distribution. The standard deviation was 7.8 years
for onset of hearing loss in the female group and three
of the 11 females (27%) had no hearing loss at ages 10.9,
11.7, and 15.8 years. Of those with hearing loss, two had
profound hearing loss from very early in life—subject
WU.WOLF-05 diagnosed at age 1.7 years and subject
WU.WOLF-19 who was profoundly deaf with no language development at the time of her adoption at age 5
(note—age 5 was used as her “official” age of hearing
loss diagnosis in the table and calculation of the average
age of onset of hearing loss as that is the youngest age
that we can be certain that she had hearing loss).

Subject

Age

Gender

DM
onset

DI
onset

Optic atrophy
onset

Hearing
loss

Diagnosed
with WFS

FH
WFS

FH DM*

FH hearing
loss*

Other problems

WU.WOLF-01

13.1

M

3.5

9

5

9

N/A

N

Father

N

GERD, constipation,
headaches, restless legs,
hypothyroidism,
hypogonadism

WU.WOLF-02

10.9

F

6

7.5

9

N

9.5

N

Mgaunt

Pgf

None

WU.WOLF-03

17.9

M

5.0

6

6

6

6

N

Mgf

mgm

GERD; restless legs;
occasional myoclonus

WU.WOLF-04

23.8

F

2.3

12

5

5

12

N

Father, pgm, paunts

Father

GERD; OCD spectrum
behaviors; constipation, loss
of taste sensation

WU.WOLF-05

13.8

F

3.8

N

12

1.7

13

N

Mgf, mggm, mgaunt

mcousin

FTT at 1 year, feeding tube at
age 2 1/2; Near-drowning
age 6 ½; celiac sprue

WU.WOLF-07

7.3

M

2.7

7

N

7

3

Y†

Mgf, paunt, puncle,
mggf, mguncle

Pgf, 3 pguncles

anxiety

WU.WOLF-09

14.3

M

10.8

14

11

N

N/A

Y‡

Distant cousin, pggf

Maunt, muncle,
pguncle, mggf

Asthma, migraines,
obstructive sleep apnea
constipation,

WU.WOLF-10

11.7

F

7.0

11

9

N

8

Y‡

Distant cousin, pggf

Maunt, muncle,
pguncle, mggf

GERD, headaches, night
terrors, constipation

WU.WOLF-11

8.3

M

7.5

10

6

8

7

Y‡

Distant cousin, pggf

Maunt, muncle,
pguncle, mggf

headaches, constipation, loss
of normal taste—“things
taste funny”

WU.WOLF-12

22.9

M

7.0

17

7

7

17

N

Father (after kidney
cancer), pgf, puncle,
pggf, mgf, pguncle

N

GERD, myoclonus,
neurogenic bladder, chronic
renal failure, hypogonadism,
loss of taste sensation

WU.WOLF-13

5.9

F

4.8

7.5

5.2

6

5.4

N

first cousin

N

Constipation

13.6

F

6.3

11.3

7.9

10.1

8.8

N

Mgf, pggm, mggf

N

None

WU.WOLF-15

10.8

F

2.8

N

7

9

7

N

N

brother

Constipation

WU.WOLF-16

25.8

F

13.1

14.6

13.6

25.8

14.9

N

pgf

pgm

None

WU.WOLF-17

17.2

F

5

N

15.3

16.3

16.6

N

Mother, maunt, mgm,
mgf, mggf, mgaunt,
mguncle, mcousin

mgaunt

None

WU.WOLF-18

11.9

M

5.1

10.33

10.1

11.9

10.6

N

Mgf

Father

None

WU.WOLF-19

11.9

F

N

N

5

Prior to 5

11

No info

No info

No info

International adoption age 5,
maternal half sibling is
healthy.
Constipation
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WU.WOLF-14
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Table 1 Subject medical and family history

WU.WOLF-22

15.8

MEAN
STD

F

14

N

13

N

14.6

14.2

6.3

5.7

3.5

10.6

8.7

9.0

10.3

3.3

3.3

6.0

4.2

N

Mggf, pgm, pgf

N

None

*Not in a person with Wolfram syndrome.
†3 distant cousins with Wolfram, parents consanguinous.
‡Sibling with Wolfram (patients WU.WOLF-11, WU.WOLF-10,WU.WOLF-09 are siblings).
Abbreviations: DI: diabetes insipidus; DM: diabetes mellitus; FH: family history; FTT: failure to thrive; GERD: gastroesophageal reflux disease; maunt: maternal aunt; mcousin: maternal cousin; mgaunt: maternal great
aunt; mgf: maternal grandfather; mggf: maternal great grandfather; mggm:maternal great grandmother; mgm: maternal grandmother; mguncle: maternal great uncle; muncle: maternal uncle; OCD: obsessive
compulsive disorder; paunt: paternal aunt; pgaunt: paternal great aunt; pgf: paternal grandfather; pgm: paternal grandmother; pguncle: paternal great uncle; puncle: paternal uncle; WFS: Wolfram Syndrome.
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Table 1 Subject medical and family history (Continued)
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Although it is not possible to determine at what age she
developed hearing loss, anecdotal evidence suggested
that she never had functional hearing. There are two of
the female subjects who developed hearing loss late, at
ages 25.8 and 16.3 years, and the remaining group of
four developed hearing loss at an average age of 7.5 ±
2.4 years.
The majority of subjects had a family history of diabetes or hearing loss in relatives who are not believed to
have WFS, though none of the relatives with hearing loss
has been tested for WFS as far as we are aware besides
those noted to have WFS. Table 2 shows the mutations
in the WFS1 gene that are present in each subject. Two
subjects had mutations found in only one allele and one
of those, c.937C > T; p.H313Y, has been reported to
present in an autosomal dominant fashion in a subject
who, like this one, presented with very early profound
hearing loss [23].
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repetitive behaviors, obsessive compulsive disorder, and
auditory hallucinations. Constipation (seven subjects,
39%) and a loss of normal taste sensation (three subjects,
17%) were reported in several.
Diabetes mellitus

The results of the mixed meal tolerance test are shown
in Table 3. WU.WOLF-19 was not diabetic either by history, by hemoglobin A1c testing, or by glucose tolerance
testing and she had a strong C-peptide response. Two
subjects (11%) had a rise in C-peptide of greater than
0.3 ng/ml in response to the mixed meal and both of
those had been diagnosed with diabetes within the past
2 years. A measureable rise in C-peptide or a C-peptide
of 1.0 or higher at baseline was found in seven (39%) of
the subjects. The mean hemoglobin A1c was 7.7%, indicating fairly good glycemic control. Only two (11%) of
subjects reported a history of diabetic ketoacidosis and
one (6%) reported a history of hypoglycemic seizures.

History and review of systems

Only four (22%) of the subjects had a normal birth history, the others reporting meconium aspiration, preterm
labor, breech presentation, or failure to progress in labor.
All of the subjects had normal language development at
the time of the clinic. A near drowning incident in early
childhood in WU.WOLF-05 had residual neurologic effects. A history of provoked seizures (due to fever or
hypoglycemia) was found in three (17%). Significant psychiatric issues were reported in two (11%), including

Neurologic and neuropsychological assessments

On exam, most subjects had some abnormal findings
(Table 4), with ten (56%) showing gait abnormalities apparent on a standard detailed neurologic exam. However,
on detailed specific testing for gait and balance disturbances, this group of WFS subjects was found to walk
more slowly, take shorter and wider steps, and spend
more time in double support than an age matched group
of healthy control individuals (data previously published

Table 2 Mutation analysis of the WFS1 gene
Subject

Allele 1

Allele 2

WU.WOLF-01

c.1060-1062delTTC; p.F354del

c.2663C>A; p.S888X

WU.WOLF-02

fc.2648del4; p.F883fsX950

No mutation

WU.WOLF-03

c.1230-1233delCTCT; p.Val412fs440Stop

c.1243-1245delGTC: p.Val415del

WU.WOLF-04

c.1112G>A; p.W371X

c.1885C>T; p.R629W

WU.WOLF-05

c.937C>T; p.H313Y

No mutation

WU.WOLF-07

c.2002C>T; p.Q668X

c.2002C>T; p.Q668X

WU.WOLF-09

c.376G>A; p.A126T

c.1838G>A;p.W613X

WU.WOLF-10

c.376G>A; p.A126T

c.1838G>A;p.W613X

WU.WOLF-11

c.376G>A; p.A126T

c.1838G>A;p.W613X

WU.WOLF-12

c.320G>A; p.G107E

c.1882C>T; p.R629W

WU.WOLF-13

c.599delT; p.L200fs286Stop

c.2254G>T; pE752Stop

WU.WOLF-14

c.817G>T; p.E273X

c.1839G>A; p.W613X

WU.WOLF-15

c.439delC, p.R147fsX163

c.1620G>A, p.W540X

WU.WOLF-16

c.1240_1242delTTC; p.F414del

c.1689_1694delCTTCTT; p.F564del; p.L565del

WU.WOLF-17

c.599T>C; p.L200P

c.695G>C; p.R232P

WU.WOLF-18

c.1251_1252delCTinsG; p.Phe417Leufsx25

c.1885C>T; p.Arg629Trp

WU.WOLF-19

c.2339G>C, p.Gly780Ala

c.2452C>T, p.Arg818Cys

WU.WOLF-22

c.605A>G; p.E202G

c.631G>A; p.D211N
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Table 3 Hemoglobin A1c and oral glucose tolerance test results
Subject

HgbA1c

Fasting glucose

Fasting C-peptide

Glucose at time 30 min

C-peptide at time 30 min

WU.WOLF-01

8.1

135

0.1

352

0.4

WU.WOLF-02

8

287

1.0

ND

ND

WU.WOLF-03

6.2

190

0.5

205

0.4

WU.WOLF-04

7.5

277

0.1

ND

ND

WU.WOLF-05

7.6

91

0.1

283

0.2

WU.WOLF-07

6.7

103

0.1

238

0.3

WU.WOLF-09

11.5

280

0.2

ND

ND

WU.WOLF-10

8

167

0.2

305

0.4

WU.WOLF-11

6.6

139

0.9

202

1.8

WU.WOLF-12

6.5

231

0.1

302

0.2

WU.WOLF-13

8.0

ND

ND

ND

ND

WU.WOLF-14

9.3

269

0.5

ND

ND

WU.WOLF-15

8.2

167

0.2

265

0.3

WU.WOLF-16

7.7

144

<0.1

194

0.2

WU.WOLF-17

9.3

257

0.2

ND

ND

WU.WOLF-18

8.3

267

0.2

ND

ND

WU.WOLF-19

5.1

85

2.1

113

9.3

WU.WOLF-22

6.5

184

0.9

266

2.6

MEAN

7.7

192.5

0.5

247.7

1.5

STD

1.4

70.9

0.5

66.4

2.7

ND = Not done.

[24,25]). Vibration sensation was impaired in eight
(44%). Other neurologic deficits included slow motor
movements in three (17%) and increased tone and brisk
deep tendon reflexes in one.
Disorders of olfaction were common (13 subjects =
72%) (Table 5). Four (57%, average age 15.6 years) of the
males has severe microsmia or total anosmia, while one
had normal olfaction at age 7.3 and two others had mild
to moderate defects (ages 14.3 and 11.9). Three (27%,
average age 13.5 years) of the females had severe
microsmia or total anosmia, while four (36%, average age
13.7 years) had normal olfaction and four (36%, average
age 16.5 years) had mild or moderate microsmia.
Verbal IQ was overall very high, with 15 of the 16
tested performing at the average range or above. The
subject with a history of near drowning performed in
the borderline range.
Clinical neuroimaging findings

Three subjects could not undergo MRI neuroimaging due
to medical implants and or anxiety. Thus, scans were
obtained on 14 subjects. Pituitary abnormalities (reduced
or absent bright spot on T1-weighted images or small posterior pituitary) were seen in seven (50%) of the scans. Of
these seven, five had diabetes insipidus, but 6 (67%) of the
subjects who were scanned who had diagnosed diabetes
insipidus did not have an abnormal pituitary. In addition,

T2-weighted or flair imaging showed signal abnormalities
in pons (one, 7%) or cortex (five, 36%).
No other clinically detectable abnormalities were noted.
However, reduced volume of the brainstem and cerebellum have been found compared to age-matched controls
(data previously published [26]).
Vision assessment

Pallor of the optic disc was present in 17 subjects (94%).
The one subject with a normal optic disc, interestingly,
did have a color vision defect, acuity defect and a cataract
(Table 6). Abnormalities in visual acuity and color vision
were present in 17 (94%). Abnormal pupillary response,
nystagmus, and cataracts were present in 11 (61%), five
(28%), and five (28%), respectively. Interestingly, six (33%)
of the subjects noted loss of their color vision around age
6, most long before any vision problems were formally diagnosed. In five (27%) of the subjects, school screening or
teachers were the first to identify a vision problem, which
led in some cases to the diagnosis of WFS. The finding of
optic atrophy led to the diagnosis of WFS in seven (39%),
but three (17%) were diagnosed with optic atrophy for 2
to 10 years before the diagnosis of WFS was made.
Audiology findings

Normal hearing was found in four subjects (22%). Profound hearing loss with onset before age 2 was present
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Table 4 Neurologic exam findings
Subject

Motor

Deep_Tendon
reflexes

Sensation

Coordination

Gait

WU.WOLF-01

Increased tone lower
extremities; intention
tremor

Brisk 3+/4 at ankles

Normal

Mild dysmetria

Unable to tandem walk

WU.WOLF-02

Normal

Normal

Normal

Normal

Normal

WU.WOLF-03

Normal

Normal

Impaired vibration (R6/L4)

Normal

Abnormal tandem walk

WU.WOLF-04

Fine finger
movements slow;
toe tapping slow

Normal

Impaired vibration (R4/L2)

Mild dysmetria
(probably due to
visual impairment)

Wide-based gait; unable
to tandem walk

WU.WOLF-05

toe tapping slow

Normal

Normal

Normal

Abnormal tandem walk

WU.WOLF-07

Normal

Normal

Normal

Normal

Normal

WU.WOLF-09

Normal

Normal

Impaired vibration (R4/L4)

Normal

Abnormal tandem walk

WU.WOLF-10

Normal

Normal

Normal

Normal

Normal

WU.WOLF-11

Normal

Normal

Normal

Normal

Abnormal tandem walk

WU.WOLF-12

Normal

Normal

Impaired vibration (R2/L2)

Normal

Abnormal tandem walk

WU.WOLF-13

Normal

Normal

Normal

Normal

Normal

WU.WOLF-14

Fine finger
movements slow

Normal

Normal

Normal

Normal

WU.WOLF-15

Normal

Normal

Normal

Normal

Normal

WU.WOLF-16

Normal

Normal

Mildly impaired vibration

Mild dysmetria

Abnormal tandem walk

WU.WOLF-17

Normal

Normal

Mildly impaired vibration

Some difficulty
hopping

Abnormal tandem walk

WU.WOLF-18

Normal

Normal

Mildly impaired vibration

Normal

Mildly abnormal tandem
walk

WU.WOLF-19

Normal

Normal

Difficult to assess,
probably normal

Normal

Normal

WU.WOLF-22

Normal

Normal

Mildly impaired vibration

Normal

Normal

in one and one other probably also had very early profound hearing loss as noted above.
With respect to vestibular function, one subject had
reduced gain of the vestibulo-ocular reflex to steps of
angular acceleration and reduced gain and increased
low-frequency phase lead on sinusoidal harmonic testing
over the range 0.025–0.5 Hz. This provides for the first
time quantitative evidence that WS can cause profound
vestibular loss in a subset of subjects.
Urology findings

One subject had chronic renal failure and neurogenic
bladder diagnosed at age 17. Enuresis was reported by
four (22%) and nocturia by three (17%). Of the 11 tested
for bladder emptying, five (45%) had elevated post-void
residual bladder volume.

Discussion
WFS is a rare monogenic disorder characterized by ER
stress in cell lines [4,6,27] and in animal models [4,5,7]
with multiple clinical manifestations. Comprehensive,

standardized phenotyping of subjects in the early stages
of this syndrome is limited. This study identified many
clinically detectable symptoms present in a group of individuals with WFS in its relatively early stages. These
data contribute to our understanding of the natural history of the clinical features of this complex syndrome,
which could facilitate diagnosis with WFS and ultimately
be useful in future therapeutic trials.
In many subjects a significant delay occurred between
the time of the diagnosis of the first signs of the syndrome
and the diagnosis of WFS. In some cases the delay led to
prolonged periods of polyuria, vision problems, or hearing
problems before those features were diagnosed and
treated. Primary care physicians, ophthalmologists, and
endocrinologists were all likely to be the caregivers first
proposing the diagnosis and school screening programs
were instrumental in identifying vision and hearing losses
in several. Earlier diagnosis may improve the quality of life
of subjects with WFS by leading to earlier diagnosis and
intervention of all of the features of WFS. Diabetes
insipidus and bladder issues in particular are difficult to
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Table 5 Olfaction, verbal IQ, neuroimaging, and audiology testing findings
Subject

Test of olfaction

Verbal IQ range

Clinical neuroimaging
findings

Hearing loss

Type of hearing loss

WU.WOLF-01

Total Anosmia

ND

ND

Yes

Sensorineural

WU.WOLF-02

Mild Microsmia

Very Superior

Normal

No

Normal

WU.WOLF-03

Total Anosmia

High Average

No pituitary bright spot

Yes—hearing aid at age 6

Sensorineural

WU.WOLF-04

Severe Microsmia

Average

ND

Yes—hearing aid at
age 12

Sensorineural

WU.WOLF-05

Normosmia

Borderline

ND

Yes—cochlear implant at
age 2

Sensorineural

WU.WOLF-07

Normosmia

High Average

Loss of pituitary bright
spot

Yes, on right only—
diagnosed at clinic

Conductive

WU.WOLF-09

Mild Microsmia

High Average

Elevated T2 in the pons

No

Normal

WU.WOLF-10

Normosmia

Average

Several areas of T2
elevation

No

Normal

WU.WOLF-11

Total Anosmia

High Average

Normal

Yes—diagnosed at clinic

Mixed

WU.WOLF-12

Total Anosmia

Average

Several small T2
anomalies

Yes—hearing aid at age 7

Sensorineural

WU.WOLF-13

Total Anosmia

Average

Small posterior pituitary

Yes—diagnosed at clinic;
no hearing aids

Sensorineural

WU.WOLF-14

Normosmia

High Average

Elevated T2 in the
periventricular occipital
lobe

Yes—hearing aids

Sensorineural

WU.WOLF-15

Total Anosmia

Superior

Faint pituitary bright spot

Yes—No hearing aids

Sensorineural

WOLF2011-16

Moderate Microsmia

High Average

Multiple T2 abnormalities,
punctate in all lobes.
Poorly seen bright
pituitary focus, either
small or absent.

Yes—No hearing aids

Sensorineural

WU.WOLF-17

Mild Microsmia

High Average

Multiple punctate T2 foci
in frontal lobes. Pituitary
bright spot not seen

Yes—No hearing aids

Sensorineural

WU.WOLF-18

Mild Microsmia

Very Superior

Absent pituitary bright
spot

Yes—hearing aids

Sensorineural

WU.WOLF-19

Mild Microsmia

ND

ND

Yes—No hearing aids

Sensorineural

WU.WOLF-22

Normosmia

Average

Several small foci of
elevated flair signal

Yes—Cochlear Implants

Sensorineural

ND = testing not done.

diagnose in a subject with pre-existing diabetes mellitus
given that polyuria and polydipsia are features of both. It
is likely that there are subjects who might be diagnosed
even before the onset of diabetes mellitus or insipidus if
there is an index of suspicion for the disorder in subjects
with hearing loss, color vision defects, gait abnormalities,
etc. We suggest that the addition of certain questions on
review of systems in subjects with diabetes, in particular,
could lead to earlier diagnosis of the syndrome. For example, color blindness and loss of olfaction are common,
even in the youngest subjects with WFS, and were frequently noticed by the subjects but not mentioned to
caregivers. Both can be rather easily and inexpensively
screened in an outpatient primary care or endocrinology
clinic setting in the event a patient reports symptoms.

The literature indicates that WFS is a progressive neurodegenerative disorder with severe neurologic abnormalities and often death during the third or fourth decade of
life. However, the order in which symptoms emerge over
time in WFS has been difficult to discern. A recent paper
surveying (but not directly assessing) 59 subjects with
WFS ranging in age from 5 to 54 found that some individuals are reported to have optic atrophy prior to the diagnosis of diabetes mellitus [17]. These investigators did not
test each subject directly, and did not assess olfaction or
color vision, so it is not clear whether these features were
also present prior to diabetes. Our study indicates that individuals with WFS may manifest multiple abnormalities
of the sensory (vision, hearing and olfactory), neurologic
and endocrine systems relatively early in the disease
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Table 6 Vision findings
Subject

Visual acuity (Eyes
together)

Abnormal pupillary
response

Color vision defect

Nystagmus

Cataracts

Optic disc
pallor

WU.WOLF-01

20/60

Yes

Strong defect

Yes

No

Yes

WU.WOLF-02

20/50

Yes

Strong defect

No

No

Yes

WU.WOLF-03

20/200

Yes

Strong defect

No

Yes: Peripheral spokes

Yes

WU.WOLF-04

Hand motion only

Yes

Strong defect

Yes

No

Yes

WU.WOLF-05

20/70

No

Moderate defect

No

Yes: Snowflake

Yes

WU.WOLF-07

20/20

No

No

No

No

Trace

WU.WOLF-09

20/250

Yes

Strong defect

No

No

Yes

WU.WOLF-10

20/250

Yes

Strong defect

No

No

Yes

WU.WOLF-11

20/125

Yes

Strong red/green defect

Yes

No

Yes

WU.WOLF-12

20/80

Yes

Strong defect

Yes

Yes: Lamellar

Yes

WU.WOLF-13

20/60

No

Moderate defect

No

No

Yes

WU.WOLF-14

20/250

Yes

Strong defect

No

No

Yes

WU.WOLF-15

20/60

Yes

Strong defect

No

No

Yes

WU.WOLF-16

20/100

No

Strong defect

No

Yes: Snowflake

Yes

WU.WOLF-17

20/25

No

Mild red/green defect

No

No

Yes

WU.WOLF-18

20/40

Yes

Strong red/green defect

Yes

No

Yes

WU.WOLF-19

20/50

No

Moderate red/green defect

No

Yes: Posterior subcapsular

No

WU.WOLF-22

20/40

No

Strong defect

No

No

Yes

process. In particular, our limited sample suggests that
optic atrophy may not always predate other clinically apparent neurologic findings (i.e. WU.WOLF-19). However,
this study is limited by the small number of subjects evaluated and may have a bias toward higher functioning families with the interest and means to attend the clinic.
Future clinics will include a larger number of subjects, but
international cooperation and standard assessment tools,
such as a rating scale for severity (e.g. the Wolfram Unified Rating Scale or WURS [28]) will be necessary to fully
address this issue. Whether the additional manifestations
we identified predict the long-term course of WFS will require longitudinal follow-up of this and other cohorts.
Since the majority of subjects with WFS have diabetes
mellitus at the time that WFS is diagnosed, these other
sensory and neurological manifestations may be important
for following the natural history of WFS and testing the
effect of potential interventions.
The WFS1 gene is one of the genes repeatedly shown
to be associated with Type 2 diabetes [29-32], indicating
that WFS may be an unusual example of a Type 2-like
diabetes mellitus of monogenic cause. This characteristic
may present an opportunity for testing diabetes therapies in a monogenic setting or further delineating the
mechanism of disease in Type 2 diabetes. The WFS1
gene encodes for the Wolframin protein that is an ER
membrane protein recently shown to control the degree
of ER stress [4]. A number of neurodegenerative

disorders including Alzheimer’s, Huntington’s, and prion
diseases have also been proposed as disorders of the ER
stress response, suggesting that WFS may also represent
a useful model of much more common neurodegenerative diseases [33]. It is encouraging that therapeutic
agents to treat ER-stress-related diseases are actively being developed [34].
WFS causes multiple endocrine and neurologic deficits, even early in the course of the disease that are clinically apparent when subjects are directly examined in a
standardized manner. The sensory system appears particularly affected, with defects found in vision, hearing,
the vestibular system, and olfaction soon after diagnosis
with diabetes. Understanding the evolution of these
symptoms over time in WFS is a necessary step towards
preparing for future clinical trials.
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